Drug shortages are no longer rare events-they’re a constant strain on hospitals, pharmacists, and patients.
As of late 2024, over 277 drugs remained in short supply across the U.S., according to Global Biodefense. These aren’t just obscure medications. They include life-saving antibiotics, chemotherapy agents, anesthetics, and even basic IV fluids like saline. Hospitals are scrambling. Pharmacists are spending hours each week tracking down alternatives. Patients are skipping doses or getting delayed treatments. And behind it all is a federal response that’s trying to catch up-but still missing the bigger picture.
The Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) is the centerpiece of the current federal strategy.
In August 2025, President Trump signed Executive Order 14178, expanding the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). This program doesn’t stockpile finished pills or injections. It stocks the raw chemical building blocks-active pharmaceutical ingredients (APIs)-needed to make 26 critical drugs. Why? Because APIs are cheaper to store, last 3 to 5 years longer than finished products, and are easier to transport than bulky vials. The goal is to have these materials ready to turn into medicine during a crisis.
The 26 drugs on the list include antibiotics like vancomycin, cancer drugs like cisplatin, and anesthetics like propofol. But here’s the problem: 98% of all drug shortages involve medications not on this list. Oncology drugs alone make up 31% of all shortages, yet only 4% of the SAPIR targets are cancer medications. That’s like stocking up on fire extinguishers but ignoring the fact that most fires start in the kitchen.
Manufacturing is still concentrated in just a few places-and that’s dangerous.
Seven out of ten sterile injectable drugs are made in just five facilities nationwide. One shutdown, one quality issue, one power outage-and suddenly, half the country runs out of a vital drug. The FDA says it resolves 85% of shortages by working with manufacturers to fix production issues or approve temporary imports. But that’s reactive. It doesn’t stop the next shortage from happening.
Even with $285 million in new CHIPS Act funding for domestic production, the U.S. is still falling behind. In 2024, the FDA approved 56 new manufacturing sites for critical drugs-but 42% of them were overseas, mostly in Ireland and Singapore. Why? Because building a new API plant in the U.S. takes 28 to 36 months to get FDA approval. In the EU, it takes 18 to 24 months. That’s a huge delay. And with just three companies controlling 68% of the sterile injectable market, there’s no real competition to keep supply stable.
Reporting requirements are weak-and that’s making shortages worse.
Since 2012, manufacturers have been legally required to tell the FDA six months in advance if they think a drug might run out. But only 58% actually do it. For small manufacturers-those with fewer than 50 employees-the compliance rate drops to just 18%. That means the FDA is often flying blind.
The FDA’s own internal review, leaked in October 2025, found that their current approach will prevent only 15% to 20% of projected shortages over the next three years. Meanwhile, the European Union has a centralized system that tracks shortages in real time and requires member states to maintain stockpiles. Since 2022, EU shortages have dropped by 37%. The U.S. has nothing close to that.
There’s a disconnect between policy and reality.
The federal government is spending money on stockpiling APIs, but it’s cutting funding for the very programs that could prevent shortages long-term. The 2026 HHS budget slashes $1.2 billion from FEMA’s emergency response and $850 million from state public health grants. Biomedical innovation funding from NIH dropped 18% between 2024 and 2025. These are the investments that build better manufacturing tech, like continuous production systems that can make drugs in days instead of months.
Even the tools meant to help hospitals are underused. The new HHS Coordination Portal, designed to give hospitals real-time visibility into drug supplies, has a usability score of just 2.1 out of 5. Only 28 of 50 states have fully implemented the supply chain mapping required by the 2025-2028 Action Plan. Rural hospitals say it takes them six months just to get the software working.
What’s actually working-and what’s being ignored?
One bright spot: the FDA’s Early Notification Pilot Program. Hospitals that signed up saw their shortage durations drop by 28%. Why? Because they reported problems early. That’s it. No fancy tech. No stockpiles. Just timely communication.
Another promising move: the FDA’s new expedited review pathway for second-source manufacturers. Right now, 14 companies are in line to start making versions of drugs that keep running out. If approved by Q2 2026, they could add redundancy for eight critical medications. That’s the kind of fix that actually reduces risk-not just moves the problem around.
But these are small steps. The real fix? Change the economics. Making a generic antibiotic or saline solution doesn’t pay well. Companies don’t invest in backup lines or extra inventory because there’s no profit in it. The AHA proposed Medicare payments to hospitals that maintain alternative supply chains. That’s a start. But until the government pays more for essential, low-margin drugs-or penalizes monopolies that control supply-shortages will keep coming.
The human cost is real-and growing.
Hospitals are spending an average of $1.2 million a year just managing shortages. Pharmacists are working 10+ hours a week tracking down drugs. In one case reported on Reddit, a pharmacist had to compound cisplatin from raw chemicals because the pre-made version wasn’t available. That’s not standard practice. That’s desperation.
Patients are skipping doses. A September 2025 survey found that 29% of Americans skipped medication because it wasn’t available-not because they couldn’t afford it. Cancer patients were hit hardest: 68% reported treatment delays or changes. One woman in Ohio had to delay her chemotherapy by three weeks because her oncologist couldn’t get the drug. She didn’t get sick because of the delay. But she lived with the fear for weeks.
What’s next? The road ahead is unclear.
The Drug Shortage Act (H.R.5316) is now in Congress. It would make it easier for pharmacists to use compounded versions of shortage drugs. That could help. But it doesn’t fix manufacturing. The Congressional Budget Office estimates it would reduce shortages by 15% to 20%-at a cost of $740 million over five years. That’s less than 0.1% of total U.S. drug spending.
Meanwhile, the FDA’s new AI-powered monitoring system is showing promise. By analyzing shipping data, batch records, and hospital orders, it can predict shortages with 82% accuracy 90 days ahead. That’s powerful. But if no one acts on the warnings, it’s just a fancy alarm with no one to hear it.
The bottom line: stockpiling isn’t enough.
The federal government is treating drug shortages like a logistics problem. They’re not. They’re an economic and structural problem. You can’t stockpile your way out of a system where making life-saving drugs isn’t profitable. You can’t outsource your way to safety when 80% of APIs come from China. And you can’t rely on hospitals to patch the cracks when they’re already overwhelmed.
The real solution needs three things: incentives for manufacturers to build redundant capacity, enforcement of reporting rules, and investment in faster, smarter production tech. Until then, shortages will keep happening. And the people paying the price will be the ones who need these drugs the most.
Comments (14)